Waking up CML leukemia stem cells for the kill.

Blood（2022）

引用 0|浏览14

暂无评分

摘要

In this issue of Blood, Zhao et al report that downregulation of MS4A3 contributes to the persistence, progression, and drug resistance of chronic myeloid leukemia (CML) to the BCR-ABL inhibitor imatinib.(1) Thus, enhancing MS4A3 levels provides a potential therapeutic strategy in treating CML.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要